Dr Bernhard Polzer and his team at the Fraunhofer Institute for Toxicology and Experimental Medicine, in Regensburg, Germany, found ANGLE’s Parsortix system streamlines the analysis of lymph nodes in melanoma.
Not only that, the new process incorporating Parsortix is more sensitive to detecting the spread of the disease to the lymph node, “greatly improving the ability to undertake key molecular analysis on cancer”.
“It is an added benefit that it also facilitates single cell analysis reducing costs,” said Polzer.
“We previously tried other CTC [circulating tumour cell] systems including antibody-based and membrane systems but these were not suitable for this process."
Polzer’s research has been published as a peer-reviewed publication in the International Journal of Cancer.
"This is another example of our leveraged approach with research customers delivering new applications for Parsortix,” said ANGLE chief executive Andrew Newland.
“There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types."
In late morning trading, shares in ANGLE were 8.2% higher at 59.50p.
-- Adds share price --